http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014142166-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-06 |
| filingDate | 2013-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014142166-A |
| titleOfInvention | POLYPEPTIDES BINDING TO CD3 |
| abstract | 1. A CD3 binding polypeptide that contains a CD3 binding domain with a reduced isoelectric point, compared to the amino acid binding domain of SEQ ID NO: 41.2. A polypeptide binding to CD3 according to claim 1, characterized in that said binding domain comprises a VH region and a VL region, while the VH region and the VL region comprise framework domains. A CD3 binding polypeptide according to claim 2, characterized in that two or more amino acids are modified in the framework regions of VH and / or VL by replacing positively charged amino acids with neutral amino acids and / or replacing neutral amino acids with negatively charged amino acids. A polypeptide that binds to CD3 according to claim 3, characterized in that the modified amino acids of the frame regions are replaced by amino acids contained within the corresponding sequence of human germline IgG. The CD3 binding polypeptide of claim 4, wherein the human germline IgG sequence contains SEQ ID NO: 43.6. The CD3 binding polypeptide of claim 4, wherein the human germline IgG sequence contains SEQ ID NO: 44.7. A polypeptide that binds to CD3, according to claim 1, characterized in that it further comprises a pre-hinge region. A CD3-binding polypeptide according to claim 7, characterized in that said pre-hinge region has a reduced isoelectric point compared to a CD3-binding polypeptide with a pre-hinge region of RRT.9. A CD3 binding polypeptide that contains a CD3 binding domain with framework regions, a pre-hinge region and a hinge region, wherein the CD3 binding polypeptide contains three or more modified amines |
| priorityDate | 2012-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 246.